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Abstract 
URINARY CATECHOLAMINES AND CORTISOL IN ATTENTION DEFICIT/ 
HYPERACTIVITY DISORDER. Marcia Dover, John Holahan, George Anderson, Bennett 
Shaywitz, Karen Marchione, Sally Shayvvitz. Department of Pediatrics, Yale University, School of 
Medicine, New Haven, CT. 
Our aim was to examine urinary catecholamines and cortisol excretion in a large sample of 
children with ADHD of varying subtypes, looking for differences between the sub-types and with respect 
*to normal controls. We also sought to establish the effect of comorbid Learning Disorder (LD) or 
Oppositional Defiant Disorder/Conduct Disorder in ADHD, and to replicate previous findings regarding 
urinary epinephrine excretion in ADHD. Boys (n = 373) between 7.5 and 13.5 years of age were recruited. 
Tests of attention, impulsivity and visio-spatial tasks were administered during the course of a three-hour 
urine collection period. Urinary excretion rates for norepinephrine, epinephrine, dopamine and cortisol . 
A ^ 
were determined. A two-way ANOVA was used to examine urinary epinephrine excretion in children with 
ADHD compared with normal children. A MANOVA was used to examine possible relationships between 
the catecholamines and ADHD, and ANOVA was used to examine possible relationships between cortisol 
and ADHD. Urinary epinephrine levels were significantly lower in children with ADHD compared with * 
normal children (F] 370 = 5.88, p - .016). There was a significant interaction between ODD/CD status and 
ADHD in urinary catecholamine levels (IVilk's /l=0.950 F9 864 =2.054, p = 0.03 1). which was attributable 
to multiple simple interactions between the AD/HD-HI sub-type and the other ADHD subtypes. There was 
a significant main effect of ADHD subtype on urinary catecholamine levels (IVilk’s /l=0.943, F gsM = 
2.054, p = 0.013), with dopamine levels significantly increased in the AD/HD-HI group. There were no 
significant differences in cortisol values among the ADHD subtypes and the control group. Lower urinary 
epinephrine excretion, without a change in urinary cortisol excretion, may be associated with ADHD. This 
finding is compatible with theories of abnormal sympathetic/adrenomedularv stress response systems in 
ADHD. 
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Introduction 
The syndrome now known as Attention Deficit/Hyperactivity Disorder ('ADHD) 
has been a source of much debate over the years. Discussions have concerned the 
diagnostic criteria, possible etiologies and the best ways to attempt to identify 
neurobiological alterations in ADHD. Each of these areas of discussion have raised 
complicated issues. Taken together, the problems have presented a serious challenge 
among investigators trying to understand the disorder. 
r 1 
Evolution of Current Nosology and the Diagnostic Dilemma 
The changes in diagnostic criteria reflect the controversy regarding the range of 
/ 
ADHD-related behavior (Morgan et ah, 1996, Lahey et ah, 1984, 1985, Cantwell and 
i 4 
Baker, 1992, Bauermeister et ah, 1992, Schneider and Tan , 1997, Weinberg and 
Brumback, 1992. What is now known as Attention Deficit/Hyperactivity Disorder 
(AD/HD) has previously carried many diagnostic titles, including Strauss syndrome, 
Hyperkinetic Behavior Syndrome, Hyperkinetic Disorder and Minimal Brain 
Dysfunction. In the 1960's, the second edition of the Diagnostic and Statistical Manual 
(DSM II) of the American Psychiatric Association (APA, 1968) recognized the 
Hyperkinetic Reaction of Childhood, and this later became Attention Deficit Disorder, 
with and without hyperactivity (ADD/H and ADD/WO respectively) in DSM III (APA, 
i 
1980). These diagnostic categories converged in DSM III-R (APA, 1987) to form the 
more heterogeneous Attention Deficit Hyperactivity Disorder (ADHD) category which 
required eight of the fourteen symptoms listed for diagnosis. In the current DSM IV 
(APA, 1994) diagnostic system, a diagnosis of Attention Deficit/Hyperactivity Disorder - 
Inattentive Type (AD/HD-IT) requires the presence of a minimum of six of the nine 
inattentive symptoms for at least six months, with less than six symptoms in the 
♦ 
1 ADHD is a generic term, for the purposes of this paper, referring to ADD. ADHD and 
AD/HD, unless otherwise specified. 
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hyperactive/impulsive category. The reverse is true for the diagnosis of Hyperactive- 
Impulsive type (AD/HD-HI. Meeting diagnostic criteria in both diagnostic categories 
fipsults in the diagnosis of Combined Type (AD/HD-CT). 
Co-morbidity between ADHD and many other behavioral and psychiatric 
disorders tends to further complicate diagnostic issues. Morgan et al (1996) noted that 
subjects with AD/HD-CT often have more associated conduct disorders and delinquent 
behaviors than those with AD/HD-IT. There were no differences between the groups 
regarding the internalizing disorders such as depression. These findings were replicated 
by Eiraldi et al.(1997), who found that those with AD/HD-CT were four times more 
likely to meet criteria for diagnosis of Oppositional Defiant Disorder (ODD) and six 
times more likely to meet diagnostic criteria for Conduct Disorder (CD) than those with 
< \ 
AD/HD-IT. Again there were no significant differences in the prevalence of disorders of 
affect or mood, although there was higher prevalence of these disorders among those with 
ADHD than non-ADHD controls. There have been reports of co-morbidity of ADHD 
with learning disability and disorders of arithmetic processing (Semrud-Clikeman et ah, 
1992, Cantwell and Baker, 1992), and ADHD is purported to be a risk factor for adult 
Psychoactive Substance Use Disorders (PSUD) (Biederman et ah, 1997, Homer et ah 
1997). 
These issues are thought to have significant impact on accuracy in diagnosing 
children with ADHD, and serve to compound the difficulties inherent in elucidating the 
etiology and pathogenesis of this disease. 
✓ 
Etiology 
A number of studies have approached the etiology and pathogenesis of ADHD. 
Genetic, developmental and environmental influences have all been proposed. 
Investigations in this area have employed methodologies from the fields of 
neurochemistry and neuropharmacology, brain imaging, and genetic analyses. 
V 
. \ 
X 
\ > ■ 
Neurochemical studies have reported catecholamine metabolite abnormalities in 
urine, plasma, and cerebrospinal fluid (CSF) (Zametkin and Rapoport, 1987, Plitska et 
ah, 1996). Neuropharmacologic studies have examined the effectiveness of drugs with 
catecholaminergic activity in treating ADHD ( for eg., Sallee et ah, 1992, Barkley et ah, 
1991, Fitzpatrick et ah, 1992, Biederman et ah, 1989, Conners et ah, 1996, Wender et ah, 
1990). 
Studies of brain morphology have supported theories of central catecholaminergic 
dysfunction in ADHD (Plitska et ah, 1996). Specifically, abnormalities in perfusion (Lou 
et ah, 1989) and size of striatal components support hypotheses of abnormal frontal and 
4 * . 
striatal dopaminergic and noradrenergic projections (Ernst and Zametkin, 1995, 
Castellanos, 1997). Electroencephalographic abnormalities also testify to cortical 
dysfunction in ADHD (Kuperman et ah, 1996, Chabot et ah, 1996). Varying size of 
* * 
regions of the corpus callosum suggests abnormal right and left brain communication, 
with evidence of impaired lateralized function (Baumgardner et ah, 1996, Lyoo et ah, 
* ‘ * 
996, Garcia-Sanchez et ah, 1997, Casey et ah, 1997). 
Genetic studies lend credence to genetic influences in ADHD (Stevenson, 1992, 
Sherman et ah, 1997a, 1997b, Levy et ah, 1997, Ernst and Zametkin, 1995), and specific 
associations have been made between dopamine-related genes and ADHD (Cook et ah, 
1995). 
Although no single study has documented abnormality in an individual system 
that can account for the full ADHD spectrum, an alternate hypothesis implicates 
abnormal sympathetic and dopaminergic interactions, which affect the ability to attend to 
task, to sustain attention with filtering of extraneous stimuli, and to shift focus. In light of 
possible abnormal stress response systems in ADHD, the hypothalamic-pituitary-adrenal 
(HPA) axis has also been examined in children with ADHD. 
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The Sympathetic Nervous System in ADHD 
The central sympathetic nervous system is comprised primarily of noradrenergic 
projections from the locus ceruleus (LC) to the ventral tegmental area (VTA) and 
prefrontal cortex (PFC) (Tassin, 1998). The LC also receives input from the nucleus 
Paragigantocellularis (PGI) in the medulla. The PGI sends excitatory input to the 
intermediolateral cells of the spinal cord as well, and thus affects peripheral nervous 
system responses (Piltska et ah, 1994). Recently, it has been found that corticotr-ophin 
/ 
; . * 
releasing factor (CRF) may affect the activity of many of these structures, and may play a 
significant role in the local stress response (Valentino et ah, 1993). The 
interomediolateral cells of the spinal cord are thought to provide primary sympathetic and 
I 
parasympathetic innervation to many organs in the body, including the adrenal medulla, 
the primary'site for adrenaline synthesis in the periphery. 
Kornetskv (1970) was first to propose a connection between increased 
norepinephrine and hyperactivity. Since then, attempts to document alterations in 
norepinephrine levels in body fluids in children with ADHD have been inconsistent 
(Zametkin and Rapoport, 1987), although there does seem to be some benefit to therapy 
that targets the proposed noradrenergic dysfunction (Arnsten et ah, 1996, Biederman pt 
ah, 1989, Gualtieri et ah, 1991, Conners et ah, 1996, Wender et ah, 1990). More 
recently, studies focusing on the adrenergic response have consistently suggested that this 
response may be blunted in children with ADHD (Klinteburg and Magnusson, 1989, 
Plitska et ah, 1994, Girardi et ah, 1995, Hanna et ah, 1996b). The effectiveness of 
pharmacotherapy also seems to be associated with an ability to increase epinephrine 
(Donnelly et ah, 1989, Elia et ah, 1990). This may lend some credence to hypotheses of 
abnormal central adrenergic function (Plitska et ah, 1994. Mefford and Potter, 1989, / . 
Tassin, 1998). A summary of recent studies (1987-1997) relating to the sympathetic 

5 
v 
nervous system in ADHD is presented in Table 1. For results of studies prior to 1987, 
please see the review by Zametkin and Rapoport (1987). 
Table 1. Studies of noradrenergic and adrenergic functioning in ADHD 
Investigators ‘ 
Sample Sizes 
ADHD Control Fluid Compound 
Findings in 
ADHD 
Ionescu et ah, 1990 12 11 Plasma EPI T EPI 
Ionescu et ah, 1990 12 11 Plasma NE None 
Plitska et ah, 1994 35 22 Urine EPI,MN 1 EPI/MN 
Plitska et ah, 1994 35 22 Urine VMA None 
Plitska et ah, 1994 35 22 Urine MHPG None 
Plitska et ah, 1994 35 22 Urine NE,NMN 1 NE/NMN 
Klinteburg, Magnusson., 1989 Urine EPI 1 EPI 
Hanna et ah, 1996a 15 16 Urine DOPEG iDOPEG 
Hanna et ah, 1996a 15 16 Urine NE 'I'EPI 
Hanna et ah, 1996a 15 ‘16 Urine EPI None 
Hanna et ah, 1996b 12 16 Urine EPI 1 EPI 
Castellanos et ah, 1994 29 202 CSF MHPG t MHPG 
Dopamine in ADHD 
Interest in the dopaminergic model of ADHD has been prompted by the 
effectiveness of stimulant treatment and the development of rat models of ADHD 
' (Shaywitz et al. , 1976, Wultz and Sagvolden, 1992, de Villiers et ah, 1995, Russel et ah. 
1995, Kohlert et ah, 1993). However, pharmacologic trials of post-synaptic 
* t 
— 
' This is a contrast group from a previous study by Kruesi et al., 1990 

dopaminergic DA agonists have failed to show beneficial effects in the treatment of 
ADHD, while, at low doses, DA antagonists have been shown to be beneficial, albeit less 
so than is commonly seen with the stimulants (Zametkin and Rapoport 1987). A 
summary of current evidence suggests that dopamine may contribute to some symptoms 
of ADHD (Levyr and Hobbes, 1988, Castellanos et ah, 1994, Rogeness et ah, 1989). 
Centrally, dopaminergic projections originating in the VTA project to the PFC, as 
well as the nucleus accumbens (nAc) and other related mesolimbic structures. 
Abnormalities in mesolimbic and nigrostriatal dopaminergic projections have been 
postulated to contribute to ADHD symptomatology (Levy, 1991), and observations in 
neuroanatomic studies are in keeping with proposed malfunction of striatal dopaminergic 
neurons (Lou et ah, 1989, Hynd et ah, 1993, Awylard et ah, 1996 and Filepek et ah, 
1997, Castellanos et ah, 1996). In the periphery, dopamine is thought to have multiple 
sources, including conversion from plasma L-DOPA (Restana et ah, 1994), 3-0- 
methyldopa (Ibarra et ah, 1996) and dopamine sulfate (Ziegler et ah, 1997), in addition to 
manufacture in sympathetic neurons and the adrenal medulla as a precursor in the 
synthesis of epinephrine and norepinephrine. 
Previous measurements of levels of dopamine or its metabolites in urine in 
children with ADHD have been inconsistent (Zametkin and Rapoport, 1987). CSF 
studies have had slightly more consistent findings, with positive correlation made 
between homovanillic acid (HVA, a metabolite of dopamine) levels and indices of 
impulsivity and hyperactivity as well as as a predictor for response to medication 
(Castellanos et ah, 1994, 1996, Rogeness et ah, 1989). 
For some time, the mesolimbic system has been thought to mediate activity levels 
In rats, stimulation of the nucleus accumbens with drugs of abuse such as amphetamine 
and cocaine is associated with increases in locomotor activity (Kelly et ah, 1975), and, 
indeed rat models of AD/HD have been associated with abnormalities in the nAc (Russel 
et ah, 1995). Recently, it has also been shown that this increase in activity secondary to 
« 
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stimulant activation of the nucleus accumbens can be reinforced with concurrent injection 
of D1 antagonists into the PFC, and can be attenuated with injection of amphetamine into 
the PFC, suggesting mesocortical regulation of mesolimbic dopaminergic activity 
(Tassin, 1998). 
1 
Cortical dopaminergic innervation is thought to perform an inhibitory function, 
decreasing the response to novel stimuli and focusing attention (Malone et ah, 1994). 
Decrease in cortical DA, then, is thought to correlate with hyperarousability, 
hyperactivity, increased distractibility and decreased attention. The mesocortical 
dopaminergic system is also very sensitive to environmental stimuli, and phasic and tonic 
regulation of its activation via central sympathetic mechanisms may have implications in 
mediating attention and arousal (Tassin, 1992). 
Sympathetic and Dopantinergic Interactions 
Taken together, the sympathetic and dopaminergic systems may explain many of 
the symptoms of ADFfD and therapies that affect both systems appear to be most 
beneficial. Some have used this observation to suggest that there is a common 
> 
biochemical mediator that results in both systems being affected. 
Dopamine, norepinephrine and epinephrine are synthesized from phenylalanine, 
through the actions of a number of enzymes, including tyrosine hydroxylase and, 
dopamine P hydroxylase (DpH), and phenylethanolamine-N-methyltransferase (PNMT), 
and metabolized by catechol-O-methyltransferase (COMT) and catecholamine oxidase 
(MAO) to their respective metabolites. Baker et ah, (1991) found decreased levels of P- 
phenylethylamine (PEA), which is related to the tyrosine precursor phenylalanine, with 
% 
no difference in levels of its metabolite phenyfacetic acid (PAA) in 24-hour urine samples 
of children with ADHD compared with normal controls. They also found decreased 
plasma phenyethylamine and tyrosine. However, Eisenberg et al., were unable to show 
benefit in reduction of ADHD symptoms with tyrosine. 
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Others have suggested that, because of possible interrelation between these two 
systems, if the symptoms of ADHD are examined as if they were heterogeneous across a 
group of diagnostic categories instead of one diagnostic category, clearer associations 
may emerge. Rogeness and colleagues (1989) examined biochemical associations with 
symptoms corresponding to DSM III criteria for attention, impulsivity and hyperactivity 
as observed across diagnostic groups of children with undersocialized conduct disorder 
(UCD), socialized conduct disorder (CD), and a group without either diagnosis. They 
found that urinary levels of NE and MHPG correlated best with symptoms of inattention. 
Levels of vanil-mandelic acid (VMA, a metabolite of norepinephrine and epinephrine), 
HVA, NE and MHPG correlated with hyperactivity, while HVA and NE levels correlated 
with impulsivity. Correlations tended to be more evident in a group defined on the basis 
of low plasma DpH. When metabolites were compared across diagnostic categories, 
positive correlations were obtained predominantly in the undersocialized conduct 
disorder group, between DA, NE, VMA and EPI and hyperactivity, and between HVA 
and VMA and impulsivity. However, Bowden et al., (1988) found that MAO and DpH 
levels were lower in subjects with ADHD and UCD compared to those without UCD, and 
that DpH values were lower in ADHD with UCD compared to controls, suggesting that 
there may be a relationship between MAO and DpH levels in CD that obscures any direct 
* 
relationship of these enzymes to ADHD. Stoff et al., (1989) found that increased levels 
of platelet MAO correlated with laboratory but not clinical measures of impulsivity, as 
evidenced by errors of comission on CPT testing, lending support to biochemical 
properties that cross diagnostic categories. 
Still others have suggested that there is some interrelation between the 
i ^ 
noradrenergic and dopaminergic systems, and an abnormality in this interrelation can 
give rise to the symptoms and associated measured abnormalities in ADHD. In review, 
Tassin (1998) proposes that there may be integration of noradrenergic circuits with 
dopaminergic circuits in the VTA and PFC. He presents the following evidence in 
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support of this interaction: 1) Lesions of ascending noradrenergic projections to the VTA 
produced decreases in dopamine in the prefrontal cortex without affecting NE in the 
prefrontal cortex or DA in the nucleus accumbens. 2) There was high correlation of 
phasic increase in NE activity with DA activity in awake, free moving rats. 3) Lesions of 
ascending NE projections abolished hyperactivity and spontaneous alterations obtained 
r 
J -m 
by destruction of DA fibers innervating the PFC. 4) The increase in Hyperactivity 
-*• ’ ♦ 
induced by stimulating the nAc with amphetamine and concurrent blockade of PFC DA 
receptors with SCH23390, a D1 receptor antagonist, was attenuated with PFC 
4 ' ■" ■" v .. ' \ * # 
pretreatment with prazosin, an a,- agonist. He used these observations to suggest that NE 
in the VTA may maintain tonic dopaminergic projections to the PFC, while NE in the 
PFC may interfere with the ability of cortical DA to manipulate mesolimbic/subcortical 
dopaminergic activity. 
While the majority of studies in ADHD tend to support abnormalities in 
sympathetic and dopaminergic function, some symptoms commonly associated with 
ADHD are comparable with those seen with impairment of the Hypothalamic-Pituitary' 
Adrenal (HPA) Axis. The HPA system is also capable of modifying the sympathetic 
response. These known qualities have led to the examination of the HPA system for 
abnormalities in ADHD. 
The HPA axis and AD/HD 
The HPA axis consists of cortical and brainstem projections to hypothalamic 
nuclei, which then mediate pituitary release of hormonal factors which target specific end 
V. i 
organ systems. Of particular importance in ADHD is ability of the HPA system to 
. / ( i 
mediate stress responses via cortisol. The hypothalamus, serving as the primer of this 
response, releases corticotropin releasing factor (CRF). This stimulates the pituitary to 
secrete adrenocorticotropic hormone (ACTH). The target organ,xhe adrenal gland, then 
secretes cortisol and increases sympathetic outflow, resulting in the appropriate stress 
T 1 
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response; the pargeting of blood flow to organs that become more metabolically active as 
part of that response. Zametkin and Rapoport (1987) provide a brief summary of studies 
and findings concerning the HPA axis and ADHD. 
Primary alterations in cortisol have not been found in children with ADHD. 
Kruesi et al. (1989) found no significant differences in urinary free cortisol output in 
children with ADHD, CD or matched controls. Schulz et al. (1997) found that there was 
no differences in plasma cortisol levels between 23 aggressive and 26 nonaggressive 
children with ADHD, and this result did not change when the subjects were compared 
depending on the presence or absence of comorbid anxiety disorders. However, without a 
control group for comparison, the possibility of altered plasma cortisol levels in children 
with ADHD relative to normal children could not be assessed. 
In assessing symptom correlations with cortisol excretion, studies have 
documented associations between low cortisol levels and aggression (Virkunen 1985), 
and negative correlations were found between cortisol levels and both inattention and 
overactivity (Scerbo and Kolko, 1994). In the latter study, cortisol levels were positively 
correlated with parent-rated internalizing behaviors, consistent with their hypothesis that 
high basal cortisol levels may correlate with internalizing behaviors. Tennes et al., 
(1986) found that increased levels of urinary cortisol were associated with increased 
social interaction which is not in agreement with the previously mentioned studies, but is 
consistent with previous work done by others (see Tennes et al., 1986). 
The neurotransmitters DA and 5-Hydroxytryptamine (5-HT) are known to 
1 
influence the hypothalamic and pituitary functioning. For example, dopamine exerts an 
inhibitory effect on the secretion of prolactin (Seri, 1995). and some studies have used 
prolactin measurements to document the effect of stimulants (Sallee et al., 1992). In their 
V 
model, Peled et al (1997) suggest that ADHD is a result of dysregulation of hypothalamic 
setpoints, secondary to prenatal or childhood stress, which causes oscillation between 
states of autonomic ovefsensitivity and hyperarousability, and those of blunted 
t 

responsivity. In keeping with this model, one would expect heightened baseline HP A 
activity (reflected in levels of ACTH and cortisol) and/or responsivity in subjects 
displaying more externalizing symptoms and lower activity or responsivity associated 
with more internalizing symptoms. 
3 * i, . . 9 
ADHD: Summary of neurochemical findings and issues 
So far, the most consistent findings lend at least indirect support to major 
proposals of central dopaminergic and sympathetic dysfunction in ADHD, and some have 
tried at length to document their peripheral connections (review by Goldstein, 1998, 
Yanagihara et ah, 1998). Studies in ADHD have been very dissimilar in subject selection 
and methodologies employed, and it is suspected that some of their inherent differences 
may contribute to the inconsistencies in neurobiological observations in ADHD. A 
\ 
particularly consistent finding, however, has been the association of blunted epinephrine 
excretion with ADHD. 
It is still unclear whether there^are measurable catecholaminergic abnormalities in 
body fluids of children with ADHD. Sample size, test conditions, type of sample 
collected and method, as well as diagnostic categorization without careful attention to 
comorbid disorders, may account for many of the variations seen in the data. A large, 
carefully diagnosed sample, with well defined test conditions and sample collection 
% ' ' ' f ' 
techniques, may serve to clarify these issues. Specifically, whether group mean 
differences exist between children with and without ADHD, or between ADHD subtypes, 
on the basis of urinary levels of EPI, NE, and DA. It would also be important to assess 
whether observed differences can be explained by existing comorbid diagnoses, 
particularly Conduct Disorder, Oppositional Defiant Disorder, Reading or Math 
4 
Disorders, or any combination of the above. 
Few studies have examined the effects of comorbid diagnoses such as behavior 
disorders (ODD/CD) or learning disorders (RD/MD) on urinary catecholamine levels. In 

12 
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one study which examined 24 hour urine collections, there was a report of increased HVA 
and epinephrine excretion in subjects with ODD/CD, compared with normal controls 
V V - * 
(Oades et ah, 1994). It would be helpful to replicate these findings in relation to 
* 
r 
epinephrine, as well as to examine the catecholamines in ODD/CD directly, as from these 
relationships we may be able to comment on the effect of having ODD/CD as comorbid 
diagnoses in children with AD/HD in terms of urinary catecholamine excretion. 
Abnormalities in cortisol levels have not been found in children with ADHD 
,although cortisol levels have been correlated with increased activity and high levels with 
inattention and other internalizing behaviors. Because of the known effects of the 
catecholamines on the HPA axis, some of the abnormalities observed in the HPA system 
may reflect abnormal neurotransmitter function, and may correct when treatment of the 
specific^abnormality commences. There is therefore a need to compare cortisol levels in 
children with ADHD relative to control groups, and further study of the effect of 
treatment on cortisol is also warranted. Finally, the possibility of a blunted stress 
response in children with ADHD suggests that an examination of stress-induced cortisol 
response in children with ADHD would be informative. 
Statement of Purpose 
Our aims are: 
ft , " v 
1. To attempt to replicate previous findings of reduced epinephrine excretion in children 
with ADHD. 
ft* * 
2. To attempt to replicate previous findings of increased urinary epinephrine excretion in 
children with ODD/CD. 
3. To assess possible abnormal interrelations between the catecholamines and cortisol in 
children with different sub-types of ADHD, controlling for comorbid learning (RD and 
A Q 
v 4 
MD) and behavioral (ODD and CD) disorders. 
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Method 
Subjects 
Participants in this study were boys (N = 373) between 7.5 and 13.5years of age, 
V 
who were recruited from the community by referral from schools, parents, professionals, 
and local media announcements over a period of five years. Male controls were recruited 
I • "V 
over the same period using newspaper advertisements, letters to schools, and posters in 
* 
local stores and libraries requesting the participation of boys without problems of 
learning or attention. Entry criteria based on telephone screening and a best estimate 
diagnosis included age, gender, no history of emotional problems or neurologic disorder. 
WISC-R (Wechsler, 1974) full scale IQ 80, English as a native language, normal or 
corrected vision and hearing, and abstinence from all medications (except Acetaminophen 
or antibiotics) for at least seven days prior to enrollment. Also, siblings were excluded 
4 / • - 
from the study population. The best estimate diagnosis was derived from the Yale 
Children's Inventory, a questionnaire formulated for parents and used to assess whether 
the child met behavioral criteria for ADHD, the Swanson, Nolan and Pelham checklist 
(SNAP), and the Diagnostic Interview Schedule for Children (DISC-R) (Shaffer et ah, 
1996). The final diagnostic categories were determined using the DISC-R (2.3, Shaffer, 
Fisher et ah, 1996), as the primary diagnostic tool. The DISC-R is a structured interview 
of the proband’s parent (usually the mother) to assess the child's psychiatric diagnostic 
status. The current version was formatted based on the newly released strict DSM IV 
criteria, and thus required meeting the same symptom requirements upon interview as the 
current DSM IV. Children were also assessed for DSM-IV defined ODD and CD. 
Learning disabilities in reading and math were assessed using low achievement and 
discrepancy criteria on the Woodcock-Johnson Psychoeducational battery (Woodcock, 
1 i 
1978). For reading disability (RD), the child's average age-adjusted standard score for 
two subtests (Letter-Word Identification and Word Attack) served as the criterion and for 
Math Disability (MD), age-adjusted standard score for the Calculation subtest served as 
the criterion. Achievement scores in the lowest quartile (age-standard score < 90) in 
. 
* 
14 
> . 
reading or math met low achievement criteria. Discrepancy criteria were established 
using a regression equations between the achievement criteria and WISC-R Full Scale IQ 
(F$IQ) derived from a normative population. 
Final groups were established by DISC 2.3 diagnosis, and included normal 
controls, AD/HD-IT, AD/HD-HI, or AD/HD-CT. The groups were subdivided separately 
to assess for effects of comorbid learning disorder, or ODD/CD. The distribution of 
subjects in the diagnostic groups is presented in Table 2. 
Table 2. Distribution of Subjects by Diagnostic Categories 
Subjects Without OD/CD 
Normal AD/HD-IT AD/HD-HI AD/HD-CT Total 
No LD 30 19 6 15 70 
LD 28 21 4 
- 4 
9 62 
Subjects With OD/CD 
No LD 18 27 13 71 129 
LD 12 20 9 71 112 
Sample Collection 
Urine was collected between the hours of nine a.m. and twelve noon, generally on 
the first day of testing. The procedure was explained to the children. Voiding was 
accomplished before the beginning of collection. The children were encouraged to drink 
several glasses of water during the collection period. In the event of test interference or 
insufficient volume, urine was re-collected on the second day of testing. These samples 
were maintained separate from those obtained on Day 1. Total urine volume was 
measured, and 5 ml of each sample was placed in storage vials provided by the Child 
Study laboratory. The storage vials contained 33 pi of 5% sodium metabisulfate 
preservative, 33 pi of EDTA, and 20 pi of glacial acetic acid. Upon receiving the 
« 
* 
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samples from the test site, 3 ml of urine was removed, and to the remainder 6 pi of the 
internal standard (HPLC methods) DHBA was added, along with an additional 20 pi of 
sodium metabisulfate. The samples were then stored at -70°C until the time of analysis. 
\ 
Testing 
Four groups of tests, each consisting of three or more tests, were administered 
during urine collection. The first group included assessments of anxiety and visio-spatial 
and motor co-ordination. These were administered at the beginning of sample collection. 
The other three groups included assessments of memory and attention, with focused and 
divided attention being assessed. 
Urine Analyses 
Urine was analyzed for concentration of DA, NE , EPI and cortisol. Urinary NE, 
DA and EPI were measured using high pressure liquid chromatography flurometry 
(Anderson et ah, 1988). Urine samples were thawed, and the pH was adjusted to 8.4-8.7 
by the addition of 3 M of pH 8.7 TRIS buffer. Fifty milligrams of alumina was then 
added, and the samples were mixed on a rotary mixer for 10 minuites. The supernantant 
was then discarded and, after washing twice with distilled water, 250 pi of 1.0 molar 
acetic acid was added to the alumina to elute the catecholamines. The supernatant eluant 
was removed and the samples were then stored in 1.5 ml polypropylene tubes for HPLC 
analysis. ^Twenty to 50 pi of each solution was injected into the chromatographic svstem. 
at a flow rate of 2.0 ml/min. For flourometric detection, the excitation wavelength was 
285 pm, and emission wavelength (with minimal background interference) was 305 pm. 
Standards were injected every 8-10,samples. Concentration (pg/ml) of the respective 
catecholamine was calculated based on the known concentration (200 pg/ml) of the 
internal standard DHBA (Aldrich Chemical Co., Milwaukee, WI 53233), the response 
ratios of the urine standards and the sample peak ratios. Cortisol was measured using 
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coated tube radioimmunoassay kits purchased from Diagnostic Systems Laboratory 
(Webster, TX). The kit included rabbit anti-cortisol antibody-labeled tubes, calibration 
standards for urine, high and low samples, and radioactive 1-125 labeled cortisol in 
sodium azide preserved buffer. 
Statistical Analysis 
Observed excretion rates for NE, EPI, DA, and cortisol were expressed as 
ng/hr/m2. Body surface area adjustnfents were made using Mosteller’s equation (Briars 
and Bailey, 1994). 
Epinephrine in ADHD and OD/CD 
Two groups were identified: those who did not meet criteria for ADHD (normal), 
and those who met any ADHD subtype criteria (ADHD). These groups were then 
subdivided into those who met OD/CD criteria and those who did not. A univariate two- 
way ANOVA was performed to determine the effects of ADHD status, OD/CD status, 
and their interaction on urinary epinephrine excretion. 
Urinary catecholamine and cortisol excretion in subtypes of ADHD 
Before proceeding with inferential statistics, the relationships among the 
dependent measures (body-surface-area adjusted urinary excretion rates of NE. EPI, DA, 
and cortisol) presented in Table 3 were estimated using Pearson product-moment 
correlations. As can be seen in the table, all three catecholamines are moderately 
intercorrelated and cortisol is correlated to an even lesser extent with any of the 
- 4 
i 
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Table 3. Pearson Correlations Among Body-Surface-Area Adjusted 
Catecholamines and Cortisol 
EPI DA Cortisol 
NE .53 .70 .29 
EPI 
* 
.52 .26 
DA V .37 
l 
Given the relative strengths of the interrelationships among the dependent 
measures, we chose to analyze the three intercorrelated catecholamines in a multivariate 
model and to analyze cortisol in a separate univariate model. We tested for the separate 
and joint effects of AD/HD status, LD status, and OD/CD status using a three-factor 
design. The AD/HD factor comprises four levels, and the OD/CD factor and LD factor 
each comprise two levels. 
Means and standard errors for the dependent measures were calculated. The three 
catecholamines were analyzed using a three-way MANOVA; cortisol was analyzed in a 
I ' 1- 
three-way ANOVA. Omnibus tests of main effects and two- and three-way interactions 
* 4 s • 
were tested at p < .05 level. Post-hoc comparisons were tested at p values Bonferroni- 
adjusted for the number of contrasts tested within each effect to maintain an effect-wise p 
< .05. For the MANOVA, omnibus and post-hoc comparisons were interpreted with 
canonical correlations. 
\ 
0 
\ 
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Results 
Epinephrine and ADHD and OD/CD 
There was no statistically significant interaction between ADHD and OD/CD 
status, nor was there a significant main effect of OD/CD status on urinary epinephrine 
" ■> ^ > 
excretion. There was, however, a significant main effect of ADHD status (F , 370 = 5.88,/? 
= .016), with ADHD being associated with lower urinary epinephrine excretion. Body- 
? 
surface-area adjusted mean epinephrine values and standard errors obtained for the 
normal group and those with ADHD are presented in Figure 1. 
Figure 1. 
Epinephrine Excretion in Normal and AD/HD Groups 
♦ 
] Mean Epinephrine 
Groups 
* 
L 
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Urinary Catecholamine Excretion in ADHD 
Means and standard errors of the body-surface-area adjusted excretion rates for 
norepinephrine, epinephrine, and dopamine in the ADHD groups and OD/CD status 
groups are presented in Table 4. The MANOVA summary is presented in Table 5. 
4 
Table 4. Means and Standard Errors of Norepinephrine, Epinephrine, and 
Dopamine Excretion by AD/HD Group and OD/CD Status 
e 
Group 
Group Normal ADHD-IT ADHD-HI ADHD-CT Total 
No OD/CD n 
i 
58 40 10 24 132 
> NE 1007±56 875168 8831139 1013190 944147 
EPI 254±19 200123 209146 201130 216116 
DA 73791398 67671480 95681979 66431639 75891331 
OD/CD n 30 47 22 142 241 
NE 1052180 879163 1001193 964136 974136 
EPI '257127 203121 272131 222112 238112 
i 
DA 80581565 68651447 74941658 74451255 74661252 
Total n 88 87 32 166 
. * NE 1030149 877146 942183 989149 
EPI 255116 201116 241128 211116 - 
DA 77191346 68161328 85311590 70441344 
I 
* 
4 
% 
V 
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The three-way interaction is not statistically significant. There is, however, a 
significant (p = .031) two-way ADHD X OD/CD interaction and a trend (p = .052) 
toward a two-way OD/CD X LD interaction. Finally, there is a significant main effect for 
ADHD group. 
Table 5. MANOVA Sum man Table for Norepinephrine, Epinephrine, and 
’■x - ' 
Dopamine 
Source df Wilk’s X F P 
AD/HD 9,864 .943 2.337 .013 
OD/CD 3,355 .992 .927 ns 
LD 3,355 .994 .665 ns 
AD/HD X OD/CD 9,864 .950 2.054 .031 
AD/HD X LD 9,864 .988 .466 ns 
OD/CD X LD 3,355 .979 2.594 .052 
AD/HD X OD/CD X LD 9,864 .984 .651 ns 
To interpret the significant two-way interaction between ADHD and OD/CD, tests 
of pairwise simple interactions were conducted. These simple interactions compared the 
differences between those without comorbid OD/CD and those with comorbid OD/CD 
from each pair of ADHD groups. The probabilities for these comparisons are presented 
in Table 6. 
¥ 
I 
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Table 6. Summary of Probabilities for MANOVA ADHD X OD/CD: Simple 
Interaction Comparisons 
I I 
Canonical Variate Loadings 
f 
Groups Contrasted P NE EPI DA 
AD/HD - IT Normal ns 
AD/HD - HI Normal .005* .104 .250 -.553 
AD/HD - CT Normal ns 
AD/HD - HI AD/HD - IT .015 .183 .284 -.492 
AD/HD - CT AD/HD - IT ns 4 , 
AD/HD - CT AD/HD - HI .001* .211 .156 -.516 
Criterion for effect-wisep < .05 after Bonferroni adjustment isp <.0083 
Statistically significant simple interactions were detected for two of six 
- comparisons. A third comparison approached, but did not reach, statistical significance. 
• « 
Each of those three comparisons included the AD/HD - HI group. The canonical variate 
loadings for the three contrasts indicate that DA contributes most to the statistically 
significant interactions. 
The significant two-way ADHD X OD/CD interaction may be interpreted in terms 
of differences between those with arid without comorbid OD/CD within each ADHD 
group. A summary of these tests of simple main effects of OD/CD status within each 
ADHD group is presented in Table 7. A statistically significant difference was found 
¥ 
between those with and without comorbid OD/CD in the AD/HD - HI group. Inspection 
of the canonical variate loadings in Table 7 and the means in Table 4 reveals that the No 
OD/CD subjects in the AD/HD - HI group exhibit a high level of DA (contributing most 
to the significant difference) and secondarily, a low level of EPI (contributing slightly to 
the significant difference) relative to the OD/CD subjects in the AD/HD -HI group. 
4 7 ) 
4 
J' * V 
* 
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Table 7. Summary of MANOVA Simple Main Effects of ODCD Within Each 
ADHD Group 
22 
Canonical Variate Loadings 
I --—— 
Group p NE EPI DA 
Normal ns 
AD/HD - IT ns 
AD/HD - HI .004* .193 .304 -.487 
AD/HD - CT ns > 
* Criterion for effect-wisep < .05 after Bonferroni adjustment isp <.0125 
To interpret the significant MANOVA main effect for ADHD group, the means 
for NE, EPI, and DA were normalized (converted to the z - distribution) and the resultant 
plot of group means is presented in Figure 2. 
Figure 2. 
, ; * V 
Catecholamines by ADHD Groups 
Epinephrine , 
Norepinephrine 
Dopamine 
ADHD Groups 
i 
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The high mean DA for the AD/HD - HI group is most pronounced. To interpret 
the main effect statistically, pairwise comparisons for the three catecholamines were 
calculated. Results of those comparisons are presented in Table 8. As would be expected 
from the analyses of the significant two-way interaction, a statistically significant 
difference was found between AD/HD -HI and AD/HD - CT groups. Furthermore, three 
other comparisons exhibited trends toward statistical significance: AD/HD - IT verses 
Normal, AD/HD - HI verses Normal, and AD/HD - HI verses AD HD - IT. 
Table 8. Summary of Probabilities for ADHD Group Pairwise Comparisons 
Groups Contrasted p 
* * 
AD/HD - IT Normal .070 
* AD,HD - HI Normal .053 
AD/HD - CT Normal ns 
AD/HD - HI AD/HD - IT .032 
AD/HD - CT AD/HD - IT ns 
AD/HD - CT AD/HD - HI .005* 
Canonical Variate Loadings 
NE EPf DA 
4 
-.135 .252 .606 
* Criterion for effect-wise/? < .05 after Bonferroni adjustment is p <.0083 
Urinary Cortisol Excretion in ADHD 
Means and standard errors of the body-surface-area adjusted cortisol for the 
ADHD groups and OD/CD status groups are presentejd in Table 9 and the ANOVA 
summary table is presented in Table 10. There are no statistically significant interactions 
or main effects. There is, however, a trend for the main effect of OD/CD status (F U54 = 
2.63, p =. 106). As can be seen in Table 9, the observed means for the four groups with 
\ ^ 
comorbid OD/CD are systematically higher than the corresponding means for the groups 
without comorbid OD/CD. 
# 
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Table 9. Means and Standard Errors of Cortisol by ADHD Group and OD/CD 
Status 
'ttr 
Group 
AD/HD Group 
> 
Overall Normal AD/HD -IT AD/HD -HI AD/HD -CT 
No OD/CD n 52 
% 
10 23 118 
1467±160 1433±202 
1 
1104+373 1417±253 1355+130 
OD/CD n 30 
t 
43 20 130 223 
1810±215 1712±178 1516±259 1440±101 1620+99 
4 
Overall n 82 76 30 153 
1639±134 1573+135 1310±22 7 1428±136 
* t > ✓ 
Table 10. ANOVA Summary for Cortisol 
Source df F P 
ADHD 3 .748 ns 
OD/CD i 2.630 .106 
LD i .650 ns 
ADHD X OD/CD 3 .316 ns 
ADHD X LD 3 .291 ns 
ODCDX LD 3 .175 ns 
ADHD X OD/CD X LD j .289 ns 
Error 354 ( 1332794.5) 
* g 
Note. Number in parentheses is a mean-squared error. 
ns: p > 0.05 
4 
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Discussion 
Our results are consistent with previous reports of reduced urinary epinephrine 
excretion in ADHD (Klinteberg and Magnusson, 1989, Hanna et al., 1996b). This 
suggests that there are differences in urinary epinephrine excretion associated with 
* 
ADHD. We are confident in the validity of this finding as, to date, this is the largest 
study of catecholamine excretion in children with ADHD. While it is unclear to what 
> 
extent comorbid disorders were excluded in the previous studies, comorbid OD/CD did 
not significantly impact on urinary epinephrine excretion in this study. 
We were unable to replicate previous fihdings of increased urinary epinephrine 
excretion in association with OD/CD (Oades et ah, 1994), although both the control 
/ 
group and those with ADHD tended to have higher epinephrine levels in association with 
OD/CD. Although there are other conditions that tend to co-exist with ADHD, 
particularly learning and affective disorders, previous reports show no effect of the 
presence of comorbid affective disorder on urinary’ catecholamines in ADHD (Morgan et 
ah, 1996, Eiraldi et ah, 1997), and our studies have shown that there was no significant 
interaction between learning disorder and ADHD diagnostic category. 
Previously thought to be derived solely from the adrenal gland, studies now have 
demonstrated other sources of urinary epinephrine. Kennedy et al.(1995) have 
demonstrated the existence of phenylethanolamine N-methyltransferase (PNMT), the 
enzyme which converts norepinephrine to epinephrine, as well as nonspecific N-methyl 
transferase (NMT), which can convert dopamine and other phenyethanolamines to 
> 
epinephrine precursors, in many other tissues, including human lung, kidney, heart, 
l 
pancreas, liver and spleen. In their studies, they obtained positive correlation between the 
presence of PNMT and epinephrine secretion within a particular tissue type. 
Although it is still thought that the majority of urinary epinephrine is derived from 
filtered plasma epinephrine, increasing evidence continues to support the existence of 
other sources for urinary epinephrine. Ziegler et al. (1997) infused 3H-Epi in humans to 
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determine what fraction of urinary epinephrine is filtered from plasma. From estimates of 
expected clearance vs. observed clearance of epinephrine, it was determined that almost 
half of urinary epinephrine is obtained from sources other than the adrenal. The authors 
hypothesized that other sources might include neuronal release in the kidney (though this 
is expected to be miniscule), as well as conversion of sulfated plasma epinephrine back to 
epinephrine by kidney sulfatases, conversion of norepinephrine to epirrephrine in the 
kidney by PNMT, conversion of other methyl amines into epinine by NMT, which can 
then be converted to epinephrine, and conversion of dopamine sulfate (from plasma) into 
epinephrine. , 
The catecholamines are known to have multiple peripheral effects in the body, 
and in particular, they direct the body's response to stress. Epinephrine and 
norepinephrine increase heart rate, and serve primarily to direct blood flow to the most 
needed areas in the flight or fight response. By stimulation of a, receptors, they cause 
peripheral vasoconstriction, while by stimulating (3, and P2 receptors, they cause increased 
heart rate and smooth muscle dilitation, respectively. The geographic location of 
adrenergic receptor subtypes in the body allow for a preferential shuttling of oxygenated 
blood to responding organs (such as skeletal muscle) and away from nonresponding 
organs (such as skin) during the stress response. 
" , * 
The finding of depressed epinephrine response to stress in children with ADHD 
compared with normal children may indicate that the type of stressor may have been 
I 
ineffective at stimulating epinephrine release. This would imply that stress responses in 
ADHD require more robust stimulation than they do in normal children, representing 
either an impairment in the elicitation of the sympathetic/adrenomedullary system in 
AD/HD, or an intrinsic deficiency in the system itself. Such impairment could occur as a 
result of decreased ability to generate epinephrine, either from norepinephrine, or from 
other known sources of urinary epinephrine, but could not reflect total adrenomedullary 
dysfunction, as there was no impact on norepinephrine levels (although it is possible that 
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norepinephrine secretion was maintained by conversion of dopamine). Yet another 
t . . * . 
explanation would be that this is a reflection of a centrally mediated change in the stress 
response in children with AD/HD. This is a most attractive hypothesis, since it would not 
l. • / 
only account for findings related to epinephrine, but to other catecholamines as well. 
Within the design of our study, however, it is also the most difficult to prove, since we 
did not directly measure any central components. Whether of central or peripheral origin, 
this finding does suggest that there is an abnormality within the stress response systems 
* 
.1 
of those with AD/HD, which manifest themselevs in lower epinephrine excretion rates. 
In addition, we found that it may be possible to distinguish the AD/HD-HI sub- 
type from other AD/HD groups as well as from normal children on the basis of urinary 
dopamine levels, as they tended to have higher levels of urinary dopamine than other 
AD/HD groups or normal controls. Sources of urinary dopamine include plasma L-dopa 
(Restana et ah, 1994), 3-O-methyldopa (Ibarra et ah, 1996) and dopamine sulfate (Ziegler 
et ah, 1997), in addition to dopamine manufactured as a precursor in the synthesis of 
norepinephrine and epinephrine. Dopamine has multiple peripheral effects, which are 
reflected by the anatomic locations of peripheral dopaminergic receptors, but it also 
extends its peripheral effects to cause feedback inhibition of some central nervous system 
components (Seri, 1995). An increase in urinary dopamine, therefore, may be explained 
* 
by decreased peripheral conversion to its successors in the metabolic pathway (NE and 
EPI) or to its metabolites. The fact that this effect is isolated to the AD/HD-HI sub-type, 
while, for example, epinephrine levels are depressed in all three AD/HD diagnostic 
i 
categories, makes this less likely. An explanation involving central sympathetic 
abnormality may explain this finding in the light of known interactions between 
* / 
prefrontal cortical noradrenergic and cortical and subcortical.dopamine and relationships 
between dopamine and hyperactivity (Tassin, 1998). It is also possible that AD/HD-HI 
may represent a separate diagnostic entity, particularly in the light of the unique observed 
interaction between epinephrine and dopamine in children with AD/HD-HI and OD/CD. 
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Alternately, a TYPE I error occurred based on the small sample size. Further 
examination is warranted, therefore, before firm theories can be developed. 
Cortisol did not serve to distinguish between ADHD subtypes or to distinguish 
A 
those with ADHD from those without ADHD. This is also in agreement with previous 
findings (Kruesi et ah, 1989, Shulz et ah, 1997), and may suggest that the abnormalities 
seen in ADHD may not involve the HPA axis directly, but its involvement may be 
contingent upon its ability to affect the symathetic stress response systems. 
In summary, the major finding of our study was lower urinary excretion of 
i 
epinephrine during the stress of cognitive testing in ADHD versus normal children. This 
* l 
result replicates previous findings of several, substantially smaller, studies, and suggests 
that the adrenomedullary response to stress is altered in ADHD children. In contrast, 
group differences were not seen for urinary indices of sympathetic neuronal activity, or 
HPA axis functioning. The results of our study, together with previous research in this 
area, indicate that further investigation targeting peripheral (adrenomedullary) and central 
epinephrine systems is warranted. Such research may provide a basis for subtyping 
ADHD patients, and may lead to the development of new pharmacological approaches to 
the treatment of ADHD. 
4 
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